Effects_NNS
of_IN
intranasal_JJ
glucocorticoids_NNS
on_IN
endogenous_JJ
glucocorticoid_NN
peripheral_JJ
and_CC
central_JJ
function_NN
._.

Glucocorticoids_NNS
are_VBP
among_IN
the_DT
most_RBS
potent_JJ
antiinflammatory_JJ
agents_NNS
that_WDT
can_MD
be_VB
used_VBN
in_IN
the_DT
treatment_NN
of_IN
rhinitis_NN
._.

Their_PRP$
mechanisms_NNS
of_IN
action_NN
are_VBP
multiple_JJ
and_CC
complex_JJ
and_CC
a_DT
number_NN
of_IN
reports_NNS
describe_VBP
significant_JJ
systemic_JJ
effects_NNS
of_IN
locally_RB
administered_VBN
glucocorticoids_NNS
._.

In_IN
order_NN
to_TO
evaluate_VB
the_DT
short-term_JJ
systemic_JJ
effects_NNS
of_IN
intranasally_RB
administered_VBN
glucocorticoids_NNS
,_,
14_CD
normal_JJ
healthy_JJ
subjects_NNS
were_VBD
treated_VBN
with_IN
two_CD
doses_NNS
of_IN
either_CC
budesonide_NN
-LRB-_-LRB-
BUD_NN
-RRB-_-RRB-
or_CC
fluticasone_NN
propionate_NN
-LRB-_-LRB-
FP_NN
-RRB-_-RRB-
for_IN
2_CD
weeks_NNS
._.

Before_IN
treatment_NN
,_,
at_IN
regular_JJ
intervals_NNS
during_IN
the_DT
treatment_NN
,_,
1_CD
week_NN
and_CC
finally_RB
6_CD
weeks_NNS
after_IN
termination_NN
of_IN
treatment_NN
,_,
the_DT
effects_NNS
on_IN
glucocorticoid_NN
receptor_NN
-LRB-_-LRB-
GR_NN
-RRB-_-RRB-
and_CC
methallothionein_NN
-LRB-_-LRB-
MTIIa_NN
-RRB-_-RRB-
mRNA_NN
expression_NN
levels_NNS
were_VBD
examined_VBN
in_IN
peripheral_JJ
lymphocytes_NNS
using_VBG
a_DT
solution_NN
hybridization_NN
assay_NN
._.

Serum_NN
cortisol_NN
,_,
osteocalcin_NN
and_CC
urinary_JJ
cortisol_NN
levels_NNS
were_VBD
also_RB
determined_VBN
._.

An_DT
insulin_NN
tolerance_NN
test_NN
-LRB-_-LRB-
ITT_NN
-RRB-_-RRB-
was_VBD
performed_VBN
at_IN
the_DT
end_NN
of_IN
the_DT
second_JJ
week_NN
of_IN
treatment_NN
and_CC
at_IN
the_DT
end_NN
of_IN
the_DT
6-week_JJ
washout_NN
period_NN
with_IN
no_DT
statistically_RB
significant_JJ
change_NN
in_IN
cortisol_NN
response_NN
._.

In_IN
peripheral_JJ
lymphocytes_NNS
,_,
GR_NN
mRNA_NN
levels_NNS
were_VBD
significantly_RB
down-regulated_VBN
._.

MTIIa_NN
mRNA_NN
levels_NNS
increased_VBD
significantly_RB
._.

Serum_NN
osteocalcin_NN
decreased_VBD
significantly_RB
during_IN
treatment_NN
with_IN
both_CC
BUD_NN
and_CC
FP_NN
._.

Serum_NN
cortisol_NN
decreased_VBD
after_IN
1_CD
week_NN
of_IN
treatment_NN
whereas_IN
urinary_JJ
cortisol_NN
was_VBD
not_RB
affected_VBN
until_IN
the_DT
second_JJ
week_NN
of_IN
treatment_NN
._.

In_IN
conclusion_NN
,_,
intranasal_JJ
glucocorticoids_NNS
at_IN
clinically_RB
recommended_VBN
doses_NNS
have_VBP
not_RB
only_RB
significant_JJ
systemic_JJ
effects_NNS
on_IN
adrenal_JJ
function_NN
,_,
but_CC
also_RB
have_VBP
an_DT
effect_NN
on_IN
specific_JJ
gene_NN
expression_NN
in_IN
peripheral_JJ
lymphocytes_NNS
._.

These_DT
effects_NNS
are_VBP
receptor-dependent_JJ
,_,
reversible_JJ
,_,
and_CC
according_VBG
to_TO
serum_NN
and_CC
urinary_JJ
cortisol_NN
levels_NNS
and_CC
ITT_NN
,_,
leave_VBP
the_DT
hypothalamic-pituitary-adrenal_JJ
function_NN
intact_JJ
._.

Finally_RB
,_,
these_DT
short-term_JJ
systemic_JJ
effects_NNS
were_VBD
not_RB
associated_VBN
with_IN
any_DT
of_IN
the_DT
noticeable_JJ
side-effects_NNS
usually_RB
observed_VBN
during_IN
long-term_JJ
treatment_NN
with_IN
glucocorticoids_NNS
._.

